Heart Failure and Cardiomyopathies

Science News

Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease
What is Quality End‐of‐Life Care for Patients With Heart Failure? A Qualitative Study With Physicians
DAPA-CKD trial at #ESC20 found dapagliflozin reduced kidney failure risk and had other CV benefits
EXPLORER-HCM trial at #ESC20 shows novel therapy that improved outcomes in patients with hypertrophic cardiomyopathy
Heart Failure in Women With Hypertensive Disorders of Pregnancy: Insights From the Cardiovascular Disease in Norway Project

Continuing Education

Registration Now Open

The CLCD Council supports AHA objectives in clinical cardiology, promotes excellent clinical care, and fosters professional development and education for clinical cardiologists. Through council-sponsored symposia, panels, and scientific conferences, partners can access and interpret new developments in the field and promote clinical cardiology to professional and lay audiences.


The CVSN Council accelerates the discovery, interpretation, and application of science to enhance cardiovascular health and treat cardiovascular diseases and stroke. The council helps develop scientific statements and advisories, guide professional education activities, provide scientific expertise, conduct research, translate findings, and promote evidence-based practices in clinical settings.


VICTORIA | Paul W. Armstrong, MD

Investigator Paul W. Armstrong, MD summarizes the results of the VICTORIA trial which he presented virtually during ACC 2020. VICTORIA examines the use of vericiguat in patients with HFrEF. See this study and other late-breaking science presentations on our AHA Science News from ACC 2020 page.

American Heart Association Professional Partners

Enjoy instant benefits!

  • Free Online Access to AHA Scientific Journals
  • Affiliate with our 16 Scientific Councils
  • Discounts on Scientific Conference Registration and Online Courses